EUVIMEDEUVIMED entdecken
Crossref

Stabilization of supersaturation for enhanced oral absorption of a BCS II drug efonidipine hydrochloride: Eudragit® L100-55-based amorphous solid dispersions

Song Huang, Yiqi Tian, Jiaxin Gao, Yuchen Zhang, Gang Cheng, Meijuan Zou, Hongyu Piao

Journal of Pharmaceutical Sciences · 2026

DOI: 10.1016/j.xphs.2026.104239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2026. Verfasst von Song Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China. Hauptthemen laut MEDLINE: Dihydropyridines, Organophosphorus Compounds, Acrylic Resins, Polymethacrylic Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Supersaturation is a widely employed strategy to improve the oral bioavailability of poorly soluble drugs, but its application is usually limited by rapid recrystallization. This study aimed to investigate the solubilization and crystallization-inhibitory effects of various polymers, including HPMCAS-LG, HPC-SL, HP-55, PVP K30, HPMC, and Eudragit® L100-55, on the BCS II drug efonidipine hydrochloride (EFH). Eudragit® L100-55 demonstrated the most effective ability to generate and maintain supersaturation of EFH in pH 6.8 phosphate buffered saline. An organic solvent-free aqueous processing strategy was successfully employed to prepare amorphous solid dispersions (ASDs) of EFH. In vitro solubility studies showed that the Eudragit® L100-55 ASDs achieved significantly higher maximum drug concentrations than crude EFH and maintained supersaturation for a prolonged duration. Consequently, in vitro studies using everted gut sacs showed that the optimized ASD enhanced the apparent permeability of EFH by nearly threefold compared to the crude drug, while the apparent permeability was comparable to that of Landel®. Pharmacokinetic studies in beagle dogs confirmed a significant improvement in oral absorption. The relative bioavailability of the optimized Eudragit® L100-55 ASD was approximately 1.5-fold higher than that of Landel®, although slightly lower Cmax and delayed tmax values were observed, indicating a slower but more sustained absorption process. The prolonged MRT further supported extended systemic exposure. the relative bioavailability of the optimized Eudragit® L100-55 ASD were 1.5 times higher than that of Landel®. The prolonged tmax and MRT suggest modified drug release characteristics. The findings demonstrate that Eudragit® L100-55-based ASDs prepared via aqueous processing represent a promising strategy for enhancing the intestinal absorption and oral bioavailability of EFH by effectively generating and stabilizing its supersaturated state. The enhancement is primarily attributed to sustained supersaturation, which maintains a higher concentration gradient and promotes absorptive flux across the intestinal membrane.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DihydropyridinesOrganophosphorus CompoundsAcrylic ResinsPolymethacrylic AcidsAnimalsSolubilityAdministration, OralDogsBiological AvailabilityMaleCrystallizationBulk DrugsDrug StabilityIntestinal AbsorptionPermeabilityNitrophenols

Stichwörter der Autor:innen

Crystallization inhibitionEfonidipine hydrochlorideEudragit® L100-55Oral absorptionSupersaturation

Substanzen

DihydropyridinesEudragit L100-55efonidipineOrganophosphorus CompoundsBulk DrugsAcrylic ResinsPolymethacrylic AcidsNitrophenols

Autor:innen und Institutionen

  • School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.
  • School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China. Electronic address: Hy_piao@126.com.

Zitieren

APA

Huang, S., Tian, Y., Gao, J., Zhang, Y., Cheng, G., Zou, M., & Piao, H. (2026). Stabilization of supersaturation for enhanced oral absorption of a BCS II drug efonidipine hydrochloride: Eudragit® L100-55-based amorphous solid dispersions. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2026.104239

Vancouver

Huang S, Tian Y, Gao J, Zhang Y, Cheng G, Zou M, et al. Stabilization of supersaturation for enhanced oral absorption of a BCS II drug efonidipine hydrochloride: Eudragit® L100-55-based amorphous solid dispersions. Journal of Pharmaceutical Sciences. 2026. doi:10.1016/j.xphs.2026.104239

BibTeX
@article{Huang2026,
  author = {Huang, Song and Tian, Yiqi and Gao, Jiaxin and Zhang, Yuchen and Cheng, Gang and Zou, Meijuan and Piao, Hongyu},
  title = {Stabilization of supersaturation for enhanced oral absorption of a BCS II drug efonidipine hydrochloride: Eudragit® L100-55-based amorphous solid dispersions},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2026},
  doi = {10.1016/j.xphs.2026.104239}
}
Kostenlos starten →